At a Glance

  • Therapeutic development company with four products in clinical stages of development
  • Two distinct technology platforms
    • CD34+ cells for ischemic repair in cardiovascular diseases and peripheral arterial diseases
    • T regulatory cells for immune modulation
  • Financially stable and debt free
    • Cash on hand ~$46 million (as of September 30, 2018)
    • Low operating cash burn
    • Debt-free
  • CD34 technology platform includes nearer-term commercial opportunities
    • CLBS12 in Phase 2 critical limb ischemia study in Japan with SAKIGAKE designation for expedited review and eligibility for early conditional approval
    • CLBS14-NORDA (previously CLBS14-RfA) in late-stage development for refractory angina
    • CLBS14-CMD in Phase 2 clinical development for coronary microvascular dysfunction supported by a grant from NIH
  • Ongoing landmark Phase 2 study of CLBS03 in recent onset type 1 diabetes
    • Strategic relationship with Sanford Research (CLBS retains all product rights)
    • ~$12.2 million CIRM grant awarded
    • ~$600,000 JDRF study subsidy
Sign up to our e-mail list to receive Caladrius announcements.

Stock Chart

Maximum 30 minute delay for quote.

Investor & Media Contact:

Caladrius Biosciences, Inc.

John D. Menditto
Vice President
Investor Relations & Corporate Communications
Phone: +1-908-842-0084
Email: jmenditto@caladrius.com